PMID- 36751175 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230209 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 15 IP - 1 DP - 2023 Jan TI - Effects of Non-surgical Periodontal Therapy on Saliva and Gingival Crevicular Fluid Levels of Chemerin in Periodontitis Subjects With and Without Type 2 Diabetes Mellitus. PG - e33388 LID - 10.7759/cureus.33388 [doi] LID - e33388 AB - Background Evidence had shown a bi-directional link between diabetes mellitus and periodontitis. Chemerin, an adipose tissue-specific adipokine plays a significant role in adipocyte initiation and differentiation that directly influences glucose metabolism, lipid metabolism, and inflammatory mediators. Non-surgical periodontal therapy (NSPT) for patients with periodontitis and diabetes mellitus improves the periodontal condition and regulates glycemic level. Aims and objectives To assess the impact of chemerin on periodontal disease and diabetes mellitus pathogenesis and to analyze the impact of NSPT on saliva and gingival crevicular fluid (GCF) chemerin levels in patients with periodontitis with and without type 2 diabetes mellitus (T2DM). Materials and methods A total of 60 patients were divided into four groups: Group I: Systemically and periodontally healthy subjects (n=15), Group II: Systemically healthy subjects with periodontitis (n=15), Group III: Subjects with periodontitis and T2DM (n=15), Group IV: Periodontally healthy subjects with T2DM (n=15). Indices and parameters like plaque index (PI), gingival index (GI), periodontal probing depth (PPD), and clinical attachment level (CAL) were assessed at baseline in all four groups and six weeks after NSPT in Group II and Group III. A glycated hemoglobin (HbA1c) test was taken to assess the patient's blood glucose level. Fasting blood sugar (FBS) level was taken at baseline in all the groups and six weeks after NSPT in Group II and Group III subjects. Saliva and GCF chemerin levels were assessed at baseline in all four groups and six weeks after NSPT in Group II and Group III subjects. Results A statistically significant difference was observed in comparing chemerin levels at baseline with all four groups (p < 0.001). After NSPT, there was a reduction in clinical parameters, FBS, and chemerin levels in Group II and Group III. A positive correlation was observed between salivary chemerin and FBS in Group II, GCF chemerin, PI, and FBS in Group II, and PPD and FBS in Group III. A negative correlation was observed between salivary chemerin and all parameters in Group II and between salivary chemerin and GCF chemerin in Group III. Conclusion Based on the observed relationship between chemerin and the parameters, their utility as a dual biomarker for diagnosis and prognosis in periodontal disease seems promising. However, further studies with a larger sample size on the role of chemerin in health and various states of diseases are required to substantiate the result of the study. CI - Copyright (c) 2023, GD et al. FAU - Gd, Gomathi AU - Gd G AD - Periodontics, Priyadarshini Dental College & Hospital, Chennai, IND. FAU - S, Gopalakrishnan AU - S G AD - Periodontology, Thai Moogambigai Dental College and Hospital, Dr MGR Educational and Research Institute, Chennai, IND. FAU - Sudhakar, Uma AU - Sudhakar U AD - Periodontics, Thai Moogambigai Dental College and Hospital, Chennai, IND. FAU - Raghavan, Anusha AU - Raghavan A AD - Public Health Dentistry, Ragas Dental College and Hospital, Chennai, IND. FAU - Narayan, Keerthi V AU - Narayan KV AD - Oral and Maxillofacial Pathology, Dr MGR Educational and Research Institute, Chennai, IND. LA - eng PT - Journal Article DEP - 20230105 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC9899038 OTO - NOTNLM OT - chemerin OT - gingival crevicular fluid (gcf) OT - periodontitis OT - scaling and root planing OT - type 2 diabetes mellites OT - unstimulated saliva COIS- The authors have declared that no competing interests exist. EDAT- 2023/02/09 06:00 MHDA- 2023/02/09 06:01 PMCR- 2023/01/05 CRDT- 2023/02/08 01:53 PHST- 2023/01/05 00:00 [accepted] PHST- 2023/02/08 01:53 [entrez] PHST- 2023/02/09 06:00 [pubmed] PHST- 2023/02/09 06:01 [medline] PHST- 2023/01/05 00:00 [pmc-release] AID - 10.7759/cureus.33388 [doi] PST - epublish SO - Cureus. 2023 Jan 5;15(1):e33388. doi: 10.7759/cureus.33388. eCollection 2023 Jan.